Company Profile

Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available for treatment of anxiety, depression and multiple CNS disorders. Vistagen’s pipeline includes six product candidates, including fasedienol (PH94B), itruvone (PH10) and three additional investigational agents belonging to a new class of drugs known as pherines, in addition to AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines, which are administered as nasal sprays, are designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can beneficially impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression and several other CNS disorders.

Vistagen Corporate Presentation


Management Team

Chief Executive Officer and Director
Vice President, Chief Financial Officer
Chief Corporate Development Officer and General Counsel

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Vistagen Therapeutics, Inc.
343 Allerton Avenue
South San Francisco, CA 94080

Investor Relations Contact

Vistagen Therapeutics

Mark McPartland
Senior Vice President, Investor Relations
+1(650) 577-3606